In This Article:
MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., received regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
"Treating chronic ITP is challenging due to the disease's diversity, making it difficult to predict individual patient responses to available treatments and not all patients can find an effective solution. The approval of fostamatinib by COFEPRIS offers physicians a new therapeutic alternative with an innovative mechanism of action,” said Dr. Luis Antonio Meillón García. Dr. Meillón García is a medical doctor from Universidad La Salle and a hematologist trained at Universidad Nacional Autónoma de México. He further specializes in hemostasis and thrombosis at the University of Rochester and currently practices professionally at Centro Médico ABC.
Knight previously announced its agreement with Rigel Pharmaceuticals, Inc. on May 24, 2022, securing exclusive rights to commercialize fostamatinib in Latin America. Fostamatinib is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently available in the United States as TAVALISSE® (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE® for the treatment of adult chronic ITP with an insufficient response to a previous treatment.
“We are excited to receive the approval of TAVALISSE® in Mexico, providing a vital new treatment option for adult patients with chronic ITP,” said Samira Sakhia, President and CEO of Knight Therapeutics. “This milestone not only marks an important step in expanding treatment options for ITP patients but also reinforces our commitment to improving patient outcomes across Latin America. We expect the launch of TAVALISSE® in Mexico in the first half of 2026.”
About ITP
In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters like thrombopoietin receptor agonists (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.